Figure 1.
Target-mediated disposition model for denosumab pharmacokinetics. Drug administered subcutaneously gets absorbed (ka) into the plasma compartment (Cp, Vc). Drug can be eliminated (kel) or rapidly bind to the pharmacological target to form a drug-ligand complex (RC). The model also includes the internalization of the drug-ligand complex (kint).